Drug Interactions between chlorzoxazone and Triumeq PD
This report displays the potential drug interactions for the following 2 drugs:
- chlorzoxazone
- Triumeq PD (abacavir/dolutegravir/lamivudine)
Interactions between your drugs
chlorzoxazone abacavir
Applies to: chlorzoxazone and Triumeq PD (abacavir / dolutegravir / lamivudine)
Administration of abacavir with other agents known to use the glucuronyl transferase or alcohol dehydrogenase metabolic pathways may increase the area under the time concentration curve for both drugs. The clinical significance is unknown.
References (1)
- (2001) "Product Information. Ziagen (abacavir)." Glaxo Wellcome
Drug and food interactions
chlorzoxazone food
Applies to: chlorzoxazone
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents such as chlorzoxazone. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills. In addition, in one small study, watercress was reported to increase chlorzoxazone peak concentrations, AUC, and half-life. The proposed mechanism is inhibition of CYP450 2E1 metabolism. The clinical significance is unknown.
MANAGEMENT: Patients receiving chlorzoxazone should be advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how chlorzoxazone affects them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Watercress should be avoided if an interaction is suspected; e.g., excess sedation, nausea, or headache occurs.
References (1)
- Leclercq I, Desager JP, Horsmans Y (1998) "Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress." Clin Pharmacol Ther, 64, p. 144-9
dolutegravir food
Applies to: Triumeq PD (abacavir / dolutegravir / lamivudine)
Food increases the extent of absorption and slows the rate of absorption of dolutegravir. When administered with a low-, moderate- or high-fat meal, dolutegravir peak plasma concentration (Cmax) increased by 46%, 52% and 67%, systemic exposure (AUC) increased by 33%, 41% and 66%, and time to reach Cmax (Tmax) increased from 2 hours to 3, 4 and 5 hours, respectively, compared to administration under fasted conditions. Dolutegravir may be taken with or without food.
References (1)
- (2013) "Product Information. Tivicay (dolutegravir)." ViiV Healthcare
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.